Sirolimus conversion for renal dysfunction in liver transplant recipients: The devil really is in the details...

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 521-522

  McKenna, G J ^a,b   Trotter, J F ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Annette C and Harold C Simmons Transplant Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; RAPAMYCIN;

ARTERY THROMBOSIS; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEPATIC ARTERY THROMBOSIS; HERPES SIMPLEX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; TREATMENT FAILURE; TREATMENT OUTCOME;

CALCINEURIN; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; SIROLIMUS;

EID: 84857647278     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03922.x     Document Type: Editorial

References (6)

1. Information for Healthcare Professions: Sirolimus (marketed as Rapamune). Available at;. Accessed November 1, 2011.
2. Molinari M, Berman K, Meeberg G, et al,. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transplant Int 2010; 23: 155-168.
3. McKenna GJ, Trotter JF, Klintmalm E, et al,. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011; 11: 2379-2387.
4. Rogers CC, Johnson SR, Mandelbrot DA, et al,. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clin Transplant 2009; 23: 887-896.
5. Watson CJ, Gimson AE, Alexander GJ, et al,. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694-1702.
6. Abdelmalek MF, Humar A, Stickel F, et al,. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012; 12: 694-705.